Why did net income decline despite higher revenue?

The original report did not specify the reason, but it could be due to higher costs or growth investments. Abbott highlighted its business mix shift toward higher-margin segments.

Which segments drove growth for Abbott?

Medical Devices and Cancer Diagnostics, both higher-margin segments, drove the growth.

What is Abbott's stock ticker?

Abbott's stock ticker is ABT, listed on the New York Stock Exchange (NYSE).

Abbott Laboratories Raises 2026 EPS Guidance After Q2 Beat

Q: What was Abbott's revenue in Q2 2026?

Abbott reported Q2 2026 revenue of $12.59 billion, up 13% year-over-year.

Q: Did Abbott raise its 2026 earnings guidance?

Yes, Abbott raised its full-year 2026 adjusted EPS guidance after better-than-expected Q2 adjusted earnings.

Abbott Laboratories (ABT) reported Q2 2026 revenue of $12.59 billion, up 13% year-over-year, while net income declined to $928 million. The company raised its full-year 2026 adjusted EPS guidance after better-than-expected adjusted earnings, driven by strong growth in higher-margin medical devices and cancer diagnostics.

Abbott Laboratories (ABT) reported its second-quarter 2026 results, with revenue rising to $12.59 billion from $11.14 billion a year earlier, a 13% increase. However, net income fell to $928 million, and diluted EPS from continuing operations declined to $0.53. Despite lower net income, adjusted earnings beat analyst expectations, prompting the company to raise its full-year 2026 adjusted EPS guidance.

Key Financial Results

Metric	Q2 2026	Q2 2025	Change
Revenue	$12.59B	$11.14B	+13%
Net Income	$928M	N/A	Decline
Diluted EPS (from cont. ops.)	$0.53	N/A	Decline

Highlights from the Report

Abbott attributed the revenue growth to strong performance in its Medical Devices and Cancer Diagnostics segments, which carry higher margins. Management noted that the business mix shift toward these segments supports long-term profitability improvement.

Future Guidance

Abbott raised its full-year 2026 adjusted EPS guidance, though the specific figure was not disclosed. The revision follows adjusted earnings that exceeded analyst estimates in Q2.

Stock Impact

The original report did not include an immediate stock reaction. However, raising guidance is typically viewed positively by investors, especially given the focus on high-margin segments.

What This Means for Investors

Abbott's shift toward medical devices and diagnostics signals a strategy to enhance profitability. The guidance raise reflects management's confidence in sustaining this trend. Investors should monitor these segments' performance in upcoming quarters.